West Coast Bio Roundup: UCLA Cashes In, BioMarin Tries Again & More
The prostate cancer drug enzalutamide (Xtandi), from San Francisco’s Medivation, has had a long, legally tangled history. Its inventors can also call it lucrative: a New York finance group that specializes in drug sales royalties has bought royalty rights from the University of California, Los Angeles, and others for more than $1 billion. Reversals of […] ... Read News
Profound Medical Corp. Announces Full Year 2015 Financial Results
TORONTO, March 02, 2016-- Profound Medical Corp., a medical device company developing and commercializing a unique, minimally invasive treatment to ablate the prostate gland in prostate cancer patients, ... Read News
NCCN Publishes New Patient Education Resources For Patients With Chronic Lymphocytic Leukemia And Hodgkin Lymphoma ...
To further educate people with Chronic Lymphocytic Leukemia and Hodgkin Lymphoma about the most effective treatment options for their disease, the National Comprehensive Cancer Network® has published the ... Read News
Tubal Ligation And Ovarian Cancer Prevention
Does having a tubal ligation (having a salpingectomy or getting your tubes tied) lower your risk of developing ovarian cancer? ... Read Article
Cancer De Prostată - Wikipedia
Bărbații care suferă de cancer la prostată nu se pot vindeca pe deplin, iar atunci când afecțiunea ajunge într-un stadiu avansat, se impune utilizarea unui tratament combinat. ... Read Article
Global Prostate Cancer Drugs Market Size, Share, Trends 2014 ...
Global Prostate Cancer Drugs Market Size, Share, Study, Report Overview TechNavio's analysts forecast the Global Prostate Cancer Drugs market to grow at a CAGR of 10.45 percent over the period 2013-2018. ... View Video
Precancerous Condition - Wikipedia, The Free Encyclopedia
A precancerous condition or premalignant condition, sometimes called a potentially precancerous condition or potentially premalignant condition, is a state of disordered morphology of cells that is associated with an increased risk of cancer. ... Read Article
No comments:
Post a Comment